1 Anthocyanin-rich extract mitigates the contribution of the pathobiont genus

2 Haemophilus in mild-to-moderate ulcerative colitis patients

- 3
- 4 Yannik Zobrist^{1†}, Michael Doulberis, MD, DVM, PhD^{2,3,4†}, Luc Biedermann, MD², Gabriel E
- 5 Leventhal, PhD^{5*} , Gerhard Rogler, MD, $PhD^{2*\Box}$
- 6 7 ¹University of Zurich, Zurich 8006, Switzerland 8 ²Department of Gastroenterology and Hepatology, Department of Medicine, Zurich University Hospital, Zurich 8091, 9 Switzerland 10 ³ Gastroklinik, Private Gastroenterological Practice, Horgen 8810, Switzerland 11 ⁴Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau, Aarau 5001, Switzerland 12 ⁵PharmaBiome AG, Schlieren 8952, Switzerland 13 14 □Address correspondence to: Prof. Rogler Gerhard, Chief of Department of Gastroenterology and Hepatology, Department of Medicine, 15 Zurich University Hospital, Zurich 8091, Switzerland. E-mail: gerhard.rogler@usz.ch
- 16

17 Ethical Considerations

18 Financial disclosures and conflicts of interest

19 MD reports traveling fees from Takeda, FALK, Abbvie as well as consulting fees from Takeda

20 LB reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Esocap, Calypso,

21 Ferring, Pfizer, Shire, Takeda, Janssen, Ewopharma. GR declares consulting fees from Abbvie,

22 Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead,

23 Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and

- 24 Zeller; speaker's honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia,
- 25 Takeda, Tillots, UCB, Vifor and Zeller; and grants support from Abbvie, Ardeypharm, Augurix,
- 26 Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB, and Zeller. GEL

- 27 is an employee and shareholder of PharmaBiome. All other authors declare no conflicts of
- 28 interest.
- 29

30 Abstract

31 **Objective:** Anthocyanins (AC) have been shown to elicit anti-inflammatory and antioxidant 32 effects in several animal models of colitis. Furthermore, AC lowered biochemical disease 33 activity in our double-blind randomized trial in patients with ulcerative colitis. Here, we 34 report on the changes in the faecal microbiome composition in the patient upon AC 35 exposure in this trial.

Methods: Ulcerative colitis patients received a 3g daily dose of an AC-rich bilberry extract (ACRE) for eight weeks. We determined the microbiome composition in longitudinal stool samples from 24 patients and quantified the degree of change over time. We also correlated the relative abundances of individual microbial taxa at different time points to faecal concentration measurements of calprotectin.

41 **Results:** Microbiome compositions did not change over time as a result of the intervention, 42 both in terms of alpha and beta diversity. Before the intervention, Haemophilus parainfluenzae was positively correlated with faecal calprotectin concentrations, and this 43 44 correlation persisted in placebo-treated subjects throughout the study. In contrast, the 45 correlation between *H. parainfluenzae* and the concentration of faecal calprotectin vanished 46 in ACRE-treated subjects, while the relative abundance of *H. parainfluenzaae* did not change. 47 **Conclusion:** Our results suggest that ACRE treatment mitigates the contribution of H. 48 parainfluenzae to inflammation. Further research is warranted to better comprehend the 49 role of microbial composition in response to medical therapy including AC-rich extract in 50 ulcerative colitis patients.

51

52 Key words: ulcerative colitis, intestinal microbiology, IBD, anthocyanin, calprotectin

53

54 Key messages

55	1.	What is already know	wn on this topic					
56		Anthocyanins are a promising therapeutic alternative for ulcerative colitis patients						
57		given their effect on t	faecal calprotectin, excellent safety profile, and low costs.					
58	2.	What this study adds	5					
59		The administration o	f anthocyanin-rich extract to ulcerative colitis patients in a Phase					
60		2a study reduced fa	ecal calprotectin concentrations by mitigating the contribution					
61		from the pathobiont	genus Haemophilus but did not affect the overall microbiome					
62		composition.						
63	3.	How this study migh	t affect research, practice or policy					
64		Our results could a	aid in targeted treatment of ulcerative colitis patients with					
65		anthocyanins, accord	ing to individual microbial composition.					
66								
67	List of	Abbreviations						
68	1.	AC	Anthocyanin					
69	2.	ACRE	Anthocyanin Rich Extract					
70	3.	ASV	Amplicon Sequence Variants					

- 714.CRPC Reactive Protein
- 725.DSSDextran Sulphate Sodium
- 73 6. GTDB Genome Taxonomy Database
- 74 7. IBD Inflammatory Bowel Disease
- 75 8. IgA Immunoglobulin A

76	9.	РСА	Principal Component Analysis
77	10.	PCR	Polymerase Chain Reaction
78	11.	SCFA	Short Chain Fatty Acids
79	12.	UC	Ulcerative Colitis
80	13.	5-ASA	5-Aminosalicylic Acid
81			

82

84 Introduction

The incidence and prevalence of inflammatory bowel disease (IBD) and in particular ulcerative colitis (UC) is rising worldwide.[1] The exact pathophysiology of UC remains unknown, with various factors thought to influence the emergence of UC,[2] complicating early detection in cases of suspected IBD, the current non-invasive diagnostic gold standard is determination of faecal calprotectin. The latter, represents a crucial non-degradable leukocyte protein with the best correlation to endoscopic inflammatory indices compared to CRP. It effectively distinguishes among mild, moderate and severe inflammation.[3]

92 Approximately two-thirds of UC patients with mild-to-moderate disease activity can be 93 successfully treated with the anti-inflammatory drug mesalamine (5-ASA). However, non-94 responders to 5-ASA treatment remain a clinical challenge, with severe cases requiring 95 invasive treatments such as colectomies. Although several other potentially effective 96 medications exist for UC, their typical safety profile is far from ideal, with substantial short 97 and long-term toxicity risks and with high annual costs for newer treatment options such as 98 biologics. [4] Because of this, there is strong interest from IBD patients for complementary 99 therapeutic options that are perceived as "natural and holistic" with fewer side effects.[5]

Anthocyanins (AC) a specific type of deglycosylated anthocyanidins, are an alternative herbal remedy for UC. ACs are concentrated in various vegetables and berries, particularly bilberries, [6,7] and are known to have antioxidant and anti-inflammatory effects [7,8] and have thus been preclinically investigated for the treatment of UC. Animal model studies have shown that AC treatment has beneficial effects on dextran sodium sulphate (DSS)-induced colitis. These effects include lower histological scores, reduced cytokine release, less colonic shortening (fibrosis), less weight loss, less hepatosplenomegaly, increased intestinal

107 permeability (which favours bacterial translocation), and lower abundances of pathogenic

108 bacteria compared to control groups.[9,10]

109 Mechanistically, it is feasible that ACs can act on the microbiome in the colon. The 110 majority of ingested ACs bypass absorption in the stomach and small intestine and reach the microbiome-rich colon. There, certain bacteria deglycosylase and metabolize ACs into 111 112 phenolic acids such as protocatechuic, vanillic, syringic, gallic, or 4-hydroxybenzoic acid.[11] 113 These bacterial fermentation derivates exhibit beneficial chemoprotective effects due to 114 their intrinsic anti-inflammatory and antioxidative properties.[12] Interestingly, positive 115 effects of AC such as increased short chain fatty acids (SCFA), reduced spleen weight, re-116 extension of colon length, or ameliorated histological scores could not be achieved or 117 replicated in germ-free mice, [9] suggesting a key role of the microbiome in the AC mode of 118 action Intake of AC also alters the intestinal microbial composition, [10,13] However, it 119 remains unclear whether the observed effects of AC on the human gut microbiome are direct, or indirect via a modulation of the microbial composition and the microbiome's 120 121 metabolic properties.

122 We recently reported on a multicentre, double-blind, randomized, placebo-controlled 123 phase II a study to confirm a therapeutic effect of 'AC rich extract' (ACRE) therapy previously 124 observed in a pilot study. [14] In the phase IIa study, we observed that faecal calprotectin 125 concentrations decreased during the treatment phase and subsequently increased again 126 after stopping ACRE therapy.[15] Here, we asked whether the effect of ACRE on faecal 127 calprotectin was mediated by the microbiome. We hypothesized that the effect acted on the 128 microbiome either directly, by inhibiting or promoting certain bacteria, or indirectly, by modulating potential negative effects of certain microbiota. To answer this, we characterized 129 130 the bacterial microbiome composition in the UC patients throughout the study and

- 131 particularly investigated whether specific genera might be associated with the observed
- 132 effect of faecal calprotectin reduction during the intervention.
- 133
- 134
- 135
- 136
- 137

138 Methods

139 Ethics

The study was carried out in accordance with principles enunciated in the current version of the Declaration of Helsinki, [16] the guidelines of Good Clinical Practice[17] issued by International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use and Swiss regulatory authority's requirements. The project was approved by the Ethics Committee Zurich (BASEC-Nr, 2017-00156).

145

146 Study design

The full protocol and study design can be found in the supplementary files. Briefly, we included individuals over 18 years of age who had a UC diagnosis for at least three months with a modified Mayo score of 6-12 and a disease activity despite therapy with 5-ASA and steroids. A detailed description of all inclusion and exclusion criteria can be found in the appendix (Supplementary Table 1).

152 Study participants were randomly assigned to either the verum or placebo group in a 153 2:1 ratio. The verum group received a daily dosage of three times 2x500mg of an ACRE 154 provided by Walther Riemer GmbH (Nimbo Green, China), corresponding to 100g dried 155 bilberries or 840mg of anthocyanins per day. The screening phase spanned four weeks, 156 followed by an eight-week intervention period and a subsequent three-week follow-up 157 phase. Three consultations were conducted during the intervention, with stool samples and 158 other relevant data collected at all time points. A detailed study procedure description is 159 available in the Appendix (Supplementary 2).

160

161 Pre-analytics

162 The stool was collected with an OMNIgene® GUT kit (DNA Genotek Inc.) and later 163 stored at -20°C until DNA extraction and sequencing (performed by Microsynth AG. Balgach. 164 Switzerland). Amplicon sequencing was performed using Illumina MiSeq paired-ends 165 sequencing technology. The hypervariable region V4 of bacterial 16S rRNA genes was 166 amplified using the primers 515F (GTGCCAGCMGCCGCGGTAA), and 806R 167 (GGACTACHVGGGTWTCTAAT) to generate an approximate amplicon size of 300bp. Multiplexed libraries were constructed with help of the two-step PCR protocol (as 168 169 recommended by Illumina). The paired-end reads were trimmed of their locus specific 170 primers and subsequently merged to in-silico reconstruct the amplified region resulting in a 171 total of 22.74 million reads, from which Amplicon Sequence Variants (ASVs) were then 172 identified.

ASVs were inferred using *Dada2* v1.18.0 with read length filtering set to 250 and 210 and maximum expected errors (maxEE) set to 4 and 5 for forward and reverse reads, respectively, and inference performed in "pseudo pool" mode. Read pairs were merged with minimum overlap (minOverlap) of 20, and bimeras were removed using the consensus method. The prepared GTDB r95 taxonomic database for Dada2 (GTDB ref, Dataset Ref) was used for taxonomic annotations via the assignTaxonomy function in Dada2.

179

180 Statistics

We obtained ASVs from 35 subjects at different study time points. After excluding data from individuals lacking baseline calprotectin measurements or with data available at fewer than 3 study time points, our final cohort comprised of 24 patients, with 17 in the verum group and 7 in the placebo group.

Genus-level relative abundances were computed by summing the counts of all ASVs that were assigned to a specific genus and normalizing by all reads. Whenever logtransformed relative abundances were computed, a pseudo count of 1 was added to the read counts.

The Shannon diversity, *H*, was computed at the relevant level of taxonomic resolution (e.g., genus). Subsequently, resulting effective number of genera was computed as the exponential of the Shannon diversity, exp(H), and represents the equivalent number of evenly distributed taxa with the same Shannon diversity. Comparisons between treatment groups were performed for each timepoint individually using Wilcoxon signed-rank tests.

We computed the Aitchison distance, i.e. the magnitude of change in microbiome composition between the centre-log-ratio transformed relative abundances. Comparisons between groups or timepoints were performed using Wilcoxon signed-rank tests.

197 The change of individual taxa (e.g., genera) over time following baseline was 198 estimated from a linear mixed model of the log10-transformed relative abundances with 199 treatment as a fixed effect and by treating timepoint as an integer including a random slope 200 for the effect of time and a random intercept for each individual.

To quantify the association of individual microbiome genera with calprotectin levels prior to the intervention, we performed individual linear mixed model regressions of the log₁₀-transformed calprotectin concentrations on the log₁₀-transformed relative abundances for those genera that were detected in at least 50% of the samples. To capture potential variability in the microbiome over time, we used both the screening and baseline abundances and accounted for subject identity as a random effect. We adjusted the p-values using the method of Benjamini-Hochberg.

208

209


210 Results

211 We previously reported that ACRE treatment reduced faecal calprotectin 212 concentrations resulting in a significantly lower concentration in the ACRE group compared 213 to the placebo group by the third visit, [15] but not at earlier visits. In order to better 214 understand the dynamics of how the faecal calprotectin over time, we estimated a per-215 subject change in faecal calprotectin using a linear mixed model. Faecal calprotectin 216 decreased steadily during treatment in the ACRE group (p = 0.0243), but did not change in 217 the placebo-treated patients (p = 0.427; Supplementary Figure 1). The concentration 218 subsequently increased again following the end of the treatment. This suggests that ACRE 219 treatment might act gradually and consistently.

220 A gradual action of ACRE on the microbiome might manifest in different ways. First, in 221 a direct way, ACRE treatment might gradually shift the microbiome composition over time 222 away from a pro-inflammatory state. Second, in an indirect way, ACRE treatment might not 223 affect the microbiome composition *per se*, but instead mitigate any pro-inflammatory impact 224 of the microbiome. In the first case, we would expect the microbiome composition to 225 gradually change during ACRE treatment—but not during placebo treatment, and in the 226 second case we would expect the microbiome to not change in either group. We did not 227 observe any evidence of a systematic change in microbiome composition in either treatment 228 group. We quantified the change in microbiome composition in terms of alpha and beta 229 diversity. For alpha diversity, we modelled the change in the effective number of genera 230 using the same linear mixed model approach as for faecal calprotectin with a treatment-231 specific slope and common intercept at baseline, and per-subject random slopes and

232 intercepts. Alpha diversity did not change over time in either treatment group (Figure 1a). 233 For beta diversity, we quantified the degree of change in terms of the Aitchison distance 234 between Baseline and Visit3 for each subject, and compared this to the distribution of 235 distances between subjects at Baseline. The Aitchison distance between Baseline and Visit3 236 was not significantly different in the ACRE and placebo groups (p = 0.697, Figure 1c), implying 237 that individual patients mostly retained their microbiome composition during treatment 238 (Figure 1b). Taken together, we do not find evidence that ACRE treatment modifies the 239 microbiome composition directly.

240



241

242 Figure 1. Microbiota composition is not affected by ACRE treatment. a. Microbiome alpha 243 diversity does not change during treatment. Blue squares and grey circles show the alpha 244 diversities at different timepoints in the study for the ACRE and placebo groups, respectively. 245 Symbols from the same patients are connected by lines. The dashed lines show the 246 estimated slopes from a linear mixed effects model that are not significantly different from 247 zero (p = 0.260 and p = 0.215). **b.** Principal component analysis (PCA) of the faecal microbiota 248 based on genus consumption over time. Each path represents an individual patient. 249 (baseline: filled shapes, follow-up: open shapes). c. Aitchison distances between subjects at 250 baseline, or between Baseline and Visit3 for the Bilberry and Placebo groups. ns = nonsignificant, *** = p value < 0.00005. 251

252

Given that ACRE treatment does not modify microbial composition directly, we next turn to the second option where ACRE acts indirectly, implying that there are certain microbiota characteristics that promote inflammation that are then mitigated by ACRE treatment. To identify such characteristics, we analysed whether certain genera correlated with faecal calprotectin concentrations before the start of the intervention. To increase statistical power, we grouped the screening and baseline samples together but accounted for subject identity as a random effect.

261 We identified 13 genera whose relative abundances were either positively or 262 negatively associated with calprotectin levels prior to the intervention (Figure 2a). Of these, 263 only two-Haemophilus and Parasutterella-remained significant after correction for 264 multiple testing at a false-discovery rate below 0.1 (Supplementary Table 3). Increasing 265 relative abundances of the genus Haemophilus were associated with higher concentrations of faecal calprotectin (p_{adi} = 0.053, conditional R² = 0.43), whereas higher relative 266 267 abundances of *Parasutterella* were associated with lower concentrations of calprotectin (p_{adi}) = 0.053, conditional R² = 0.52) (Figure 2b). 268

This analysis identifies *Haemophilus* abundance as a potential contributor to inflammation and conversely *Parasutterella* as a potential mitigator of inflammation in the subjects before initiating treatment. We presumed that if these contributions were robust, then they should persist throughout the study in the placebo-treated individuals in which we do not expect any modulation of the interaction between microbiome and inflammation.

274

275

medRxiv preprint doi: https://doi.org/10.1101/2024.09.30.24314597; this version posted October 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




Figure 2. Genera associated with high/low fecal calprotectin concentration prior to the intervention. a. Volcano plot of the regression slopes and their individual p-values. Genera with p < 0.05 are labelled. b. Visualization of the relationship between relative abundance (xaxis) and fecal calprotectin concentrations for the two genera with a false discovery rate < 0.1. Samples from the same individual at Screening (circles) and Baseline (squares) are connected with a line.

283

284


The association of *Haemophilus* and faecal calprotectin persisted in the placebo group 285 286 throughout the intervention, while the association for Parasutterella did not. We used all sampling points after the start of the intervention, i.e., visits 1-3 and follow-up and 287 accounted for subject identity as a random intercept. Haemophilus relative abundance 288 289 remained significantly correlated with faecal calprotectin concentrations in the placebo group after the start of the intervention (p = 0.0347, conditional $R^2 = 0.367$, Supplementary 290 291 Figure 2). In contrast, the negative correlation between *Parasutterella* Relative abundance and faecal calprotectin was not significant after the start of the intervention (p = 0.673, 292 conditional $R^2 = 0.28$). This suggests that *Haemophilus* might indeed contribute directly to 293 294 inflammation.

We hypothesized that if ACRE directly exerts an influence on the microbiota, for instance by depleting *Haemophilus* abundance, then a correlation between *Haemophilus* and faecal calprotectin would be expected to remain in the ACRE group, with a potential overall decrease in *Haemophilus* abundance. Alternatively, if ACRE were to modify the mechanism with which *Haemophilus* contributes to inflammation, then we would not expect an effect on *Haemophilus* abundance but rather that there would nevertheless be a decrease in faecal calprotectin concentration.

To test these hypotheses, we first investigated whether the relative abundance of *Haemophilus* changed during ACRE treatment. Second, we investigated whether the relationship between the abundance of *Haemophilus* and faecal calprotectin concentration remained in the ACRE group after the start of the intervention.

306 ACRE treatment did not impact Haemophilus abundance but did negate the 307 association between Haemophilus and faecal calprotectin. The estimated change in 308 Haemophilus abundance over time in the ACRE group was not significantly different from 309 zero (p = 0.345, Figure 3). However, faecal calprotectin was no longer significantly associated 310 with *Haemophilus* relative abundance after the start of the intervention (p = 0.422, conditional $R^2 = 0.42$) (Figure 4). Closer inspection of the ASVs that were identified as 311 312 Haemophilus in our data revealed only a single ASV that mapped with 100% identity to the 313 strain Haemophilus parainfluenzae ATCC 33392. Taken together, these results indicate that ACRE treatment modifies the interaction between Haemophilus parainfluenzae and 314 315 inflammation, rather than by directly decreasing *Haemophilus* abundance.


- 316
- 317
- 318



319

Figure 3. *Haemophilus* relative abundance remains stable during treatment. Each small circle shows the relative abundance of the genus *Haemophilus* in either the placebo group (grey) or ACRE group (blue). The large circles show the mean within the groups for each timepoint. The dashed lines show the estimated regression slope of log₁₀ relative abundance over time.

- 325
- 326
- 327
- 328



329

Figure 4. *Haemophilus* relative abundance is not significantly correlated with faecal calprotectin during ACRE treatment. Each point corresponds to a sample from a patient at visit 1 (circles), visit 2 (triangles), or visit 3 (squares). The dashed line shows the estimated regression slope from a linear mixed model with subject as a random effect.

- 334
- 335
- 336
- 337

339 Discussion

340 In our study we aimed to investigate to what degree the previously observed effect of 341 ACRE treatment on lowering faecal calprotectin concentrations in a clinical study in subjects 342 with mild to moderate UC was linked to a modulation of the microbiome in these subjects. . 343 Unexpectedly, we did not observe any substantial shifts in microbiome composition induced 344 by ACRE treatment. Instead, we observed that ACRE treatment mitigated the association 345 between the abundance of the genus *Haemophilus* in the faecal microbiome and the faecal 346 calprotectin concentration. Prior to initiating the study, patients with higher abundances of 347 Haemophilus also had higher concentrations of faecal calprotectin and this correlation 348 persisted in the placebo-treated patients. In contrast, the correlation vanished during ACRE 349 treatment. Therefore, ACRE administration did not reduce faecal calprotectin concentrations 350 by directly modulating the microbial composition, but rather by indirectly affecting the 351 proinflammatory mechanisms of bacterial taxa such as Haemophilus.

352 The observation that treatment with AC did not affect the microbiome composition is 353 unexpected based on previous mouse studies in the literature of AC impacting microbiome 354 alpha and beta diversity in UC. Two studies observed an increased Shannon index and a 355 significant beta diversity shift after ingesting 200mg/kg AC for 7 or 17 days, 356 respectively.[10,18] Another four-week study with daily intake of 3.47mg suggested a 357 potential increase in alpha diversity post-anthocyanin intake.[19] However, these studies 358 were performed in mice with DSS-induced colitis, used sources of AC other than bilberries 359 that may impact the effect, [20] and had higher daily doses per kg body weight (173-360 200mg/kg) compared to our study (ca. 11.8mg/kg; assuming an average European weight of 361 71kg).

The genus *Haemophilus* has previously been reported to be increased in abundance in IBD patients.[21–24] The positive correlation we observed between the relative abundance of *Haemophilus* and faecal calprotectin concentrations is in line with a previous work that found an association of *Haemophilus* with more severe disease.[25]

366 Consistent with our results, two studies have reported an increased presence of 367 Haemophilus spp. in UC patients that is particularly pronounced in active stages. [26, 27] Thus, 368 emerging evidence suggests that *Haemophilus spp.* may be considered as a potentially 369 pathogenic genus for UC. Moreover, studies have demonstrated that Haemophilus 370 parainfluenza exhibits strong IgA coating in individuals with UC.[28] IgA, the predominant 371 dimeric antibody in the intestinal mucosa, plays a crucial role in coating and neutralizing 372 pathogens. IgA coating is also observed in endogenous microbiota, though to a lesser extent 373 than with pathogens. [29] Given that certain genera influencing UC severity share similarities 374 with pathogens, [30] Palm et al. and Shapiro et al. suggest pathogenic microbiota may be 375 more heavily coated with IgA.[31.32] Furthermore, more active UC is associated with 376 increased IgA coating and higher faecal IgA levels[33] and on the other hand mice with 377 elevated IgA levels and therefore higher amount of coated bacteria demonstrate greater 378 resistance to DSS-induced murine colitis.[34] Finally, blueberry ingestion is linked to 379 increased IgA secretion.[35,36] In summary, it is reasonable to hypothesize that IgA secretion 380 is increased by higher inflammatory activity or pathogenic microbes, thus coating the more 381 pathogenically active microbiota trying to provide control of colitis. AC, in turn, seem to 382 facilitate IgA production, exerting their potentially anti-inflammatory effect on UC. ACRE may 383 stimulate IgA secretion resulting in a more intensive coating of pathobiont Haemophilus, 384 thereby reducing its proinflammatory potential. However, other potential anti-inflammatory

385 mechanisms of ACRE via the microbiome are conceivable, such as promoting beneficial SCFA

386 production, reducing colonic shortening, or enhancing epithelial barriers.[9,13]

387 The observation of a clinically meaningful decrease in a key biochemical parameter 388 that is linked to disease activity in UC suggests that AC might be considered as a viable 389 treatment option in UC that warrants further evaluation. While it is unlikely that 390 anthocyanins exert their effects exclusively by mitigating the proinflammatory potential of 391 Haemophilus spp., their potential benefits may be more pronounced in individuals with 392 higher *Haemophilus spp.* abundance in their intestinal microbiome. Additionally, probiotic 393 therapies might prove valuable in reducing pathobionts such as Haemophilus spp. in UC 394 patients, fostering a more favourable microbial microenvironment for the disease. 395 Nevertheless, larger studies are essential to reach accumulation of positive evidence and 396 secondarily a consensus on the composition of the microbiota and its analysis in order to 397 take a step towards personalized medicine, especially with complementary options such as 398 ACRE.

399 A particular strength of our study is the randomized double-blind design with a novel 400 intervention among the first to investigate the impact of a high-dose anthocyanin 401 intervention on the microbiome composition in UC patients. While there are already some 402 investigations on this topic in animal models, [9, 10, 13, 18–20] this is to the best of our 403 knowledge the first human data. Another strength of our study is that we repeated 404 assessments of the key parameters, microbiome composition and faecal calprotectin 405 concentration, over time for the same subjects that enables us to account for some of the 406 intra-individual variability.

407 Several limitations of our study have to be acknowledged. Firstly, our sample size 408 comprising of only 24 patients is rather small and for this reason we have taken care that our

409 statistical inferences are appropriate A further limitation that is shared by most other 410 microbiome studies is that our work considers only relative abundances of microbial taxa and 411 focuses primarily on faecal calprotectin. We did not investigate other related parameters 412 such as the microbial metabolome or immunologic factors like intestinal IgA production. 413 Finally, we exclusively focused on bacterial taxa of the intestinal microbiota and did not take 414 other microbes into account, such as fungi, viruses, or protozoa.

415 In conclusion, we provide evidence that the anti-inflammatory effect of the ACRE 416 intervention was not mediated via a relevant modulation of the microbiome, as originally 417 thought, but rather via a regulation of the pro-inflammatory effect of its pathobionts such as Haemophilus parainfluenzae. Whether this effect is directly caused by the administered AC 418 419 or rather by their degradation products after metabolization by the microbiome remains 420 unclear. Regarding the intake of AC, the exact interaction of anthocyanins and the 421 microbiome in UC has not yet been clarified and remains vague. Which biochemical and 422 physiological links are involved and what might be the overall effect on the disease needs to 423 be further investigated.

424

425 Acknowledgements

The authors wish to thank all the patients for their cooperation as well as their families
for their support during this endeavour.

428

429 Ethical Considerations

430 Financial disclosures and conflicts of interest

431 MD reports traveling fees from Takeda, FALK, Abbvie as well as consulting fees from Takeda

432	LB reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Esocap, Calypso,
433	Ferring, Pfizer, Shire, Takeda, Janssen, Ewopharma. GR declares consulting fees from Abbvie,
434	Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead,
435	Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and
436	Zeller; speaker's honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia,
437	Takeda, Tillots, UCB, Vifor and Zeller; and grants support from Abbvie, Ardeypharm, Augurix,
438	Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB, and Zeller. GEL
439	is an employee and shareholder of PharmaBiome. All other authors declare no conflicts of
440	interest
441	
442	

443 References

 Ungaro R, Mehandru S, Allen PB, <i>et al.</i> Ulcerative colitis. <i>The Lancet.</i> 2017;389:1756– 70. doi: 10.1016/S0140-6736(16)32126-2 Schoepfer AM, Beglinger C, Straumann A, <i>et al.</i> Ulcerative colitis: Correlation of the Rachmilewitz Endoscopic Activity Index with fecal calprotectin, clinical activity, C- reactive protein, and blood leukocytes. <i>Inflamm Bowel Dis.</i> 2009;15:1851–8. doi: 10.1002/ibd.20986 Rogler G, Bernstein CN, Sood A, <i>et al.</i> Role of biological therapy for inflammatory bowel disease in developing countries. <i>Gut.</i> 2012;61:706–12. doi: 10.1136/gutjnl- 2011-300613 Langhorst J, Anthonisen IB, Steder-Neukamm U, <i>et al.</i> Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: Perceived stress is a potential indicator for CAM use. <i>Complement Ther Med.</i> 2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008 	1	bowel disease in the 21st century: a systematic review of population-based studies.
 Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: Correlation of the Rachmilewitz Endoscopic Activity Index with fecal calprotectin, clinical activity, C- reactive protein, and blood leukocytes. <i>Inflamm Bowel Dis</i>. 2009;15:1851–8. doi: 10.1002/ibd.20986 Rogler G, Bernstein CN, Sood A, et al. Role of biological therapy for inflammatory bowel disease in developing countries. <i>Gut</i>. 2012;61:706–12. doi: 10.1136/gutjnl- 2011-300613 Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: Perceived stress is a potential indicator for CAM use. <i>Complement Ther Med</i>. 2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008 		2 Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. The Lancet. 2017;389:1756–
 Rachmilewitz Endoscopic Activity Index with fecal calprotectin, clinical activity, C- reactive protein, and blood leukocytes. <i>Inflamm Bowel Dis</i>. 2009;15:1851–8. doi: 10.1002/ibd.20986 Rogler G, Bernstein CN, Sood A, <i>et al.</i> Role of biological therapy for inflammatory bowel disease in developing countries. <i>Gut</i>. 2012;61:706–12. doi: 10.1136/gutjnl- 2011-300613 Langhorst J, Anthonisen IB, Steder-Neukamm U, <i>et al.</i> Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: Perceived stress is a potential indicator for CAM use. <i>Complement Ther Med</i>. 2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008 		
 reactive protein, and blood leukocytes. <i>Inflamm Bowel Dis</i>. 2009;15:1851–8. doi: 10.1002/ibd.20986 Rogler G, Bernstein CN, Sood A, <i>et al</i>. Role of biological therapy for inflammatory bowel disease in developing countries. <i>Gut</i>. 2012;61:706–12. doi: 10.1136/gutjnl- 2011-300613 Langhorst J, Anthonisen IB, Steder-Neukamm U, <i>et al</i>. Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: Perceived stress is a potential indicator for CAM use. <i>Complement Ther Med</i>. 2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008 	3	3 Schoepfer AM, Beglinger C, Straumann A, <i>et al.</i> Ulcerative colitis: Correlation of the
 452 10.1002/ibd.20986 453 4 Rogler G, Bernstein CN, Sood A, <i>et al.</i> Role of biological therapy for inflammatory 454 bowel disease in developing countries. <i>Gut.</i> 2012;61:706–12. doi: 10.1136/gutjnl- 455 2011-300613 456 5 Langhorst J, Anthonisen IB, Steder-Neukamm U, <i>et al.</i> Patterns of complementary and 457 alternative medicine (CAM) use in patients with inflammatory bowel disease: 458 Perceived stress is a potential indicator for CAM use. <i>Complement Ther Med.</i> 459 2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008)	Rachmilewitz Endoscopic Activity Index with fecal calprotectin, clinical activity, C-
 453 4 Rogler G, Bernstein CN, Sood A, <i>et al.</i> Role of biological therapy for inflammatory 454 bowel disease in developing countries. <i>Gut.</i> 2012;61:706–12. doi: 10.1136/gutjnl- 455 2011-300613 456 5 Langhorst J, Anthonisen IB, Steder-Neukamm U, <i>et al.</i> Patterns of complementary and 457 alternative medicine (CAM) use in patients with inflammatory bowel disease: 458 Perceived stress is a potential indicator for CAM use. <i>Complement Ther Med.</i> 459 2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008 		reactive protein, and blood leukocytes. <i>Inflamm Bowel Dis</i> . 2009;15:1851–8. doi:
 454 bowel disease in developing countries. <i>Gut</i>. 2012;61:706–12. doi: 10.1136/gutjnl- 455 2011-300613 456 5 Langhorst J, Anthonisen IB, Steder-Neukamm U, <i>et al.</i> Patterns of complementary and 457 alternative medicine (CAM) use in patients with inflammatory bowel disease: 458 Perceived stress is a potential indicator for CAM use. <i>Complement Ther Med</i>. 459 2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008 		10.1002/ibd.20986
 2011-300613 Langhorst J, Anthonisen IB, Steder-Neukamm U, <i>et al.</i> Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: Perceived stress is a potential indicator for CAM use. <i>Complement Ther Med.</i> 2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008 	4	4 Rogler G, Bernstein CN, Sood A, <i>et al.</i> Role of biological therapy for inflammatory
 456 5 Langhorst J, Anthonisen IB, Steder-Neukamm U, <i>et al.</i> Patterns of complementary and 457 alternative medicine (CAM) use in patients with inflammatory bowel disease: 458 Perceived stress is a potential indicator for CAM use. <i>Complement Ther Med.</i> 459 2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008 	Ļ	bowel disease in developing countries. <i>Gut</i> . 2012;61:706–12. doi: 10.1136/gutjnl-
 457 alternative medicine (CAM) use in patients with inflammatory bowel disease: 458 Perceived stress is a potential indicator for CAM use. <i>Complement Ther Med</i>. 459 2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008 		2011-300613
 458 Perceived stress is a potential indicator for CAM use. <i>Complement Ther Med</i>. 459 2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008 	5	5 Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Patterns of complementary and
459 2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008	,	alternative medicine (CAM) use in patients with inflammatory bowel disease:
•	1	Perceived stress is a potential indicator for CAM use. <i>Complement Ther Med</i> .
460 6 Wing-kwan Chu, Sabrina C. M. Cheung, Roxanna A. W. Lau IFFB. <i>Chapter 4: Bilberry</i>)	2007;15:30–7. doi: 10.1016/j.ctim.2006.03.008
	6	6 Wing-kwan Chu, Sabrina C. M. Cheung, Roxanna A. W. Lau IFFB. Chapter 4: Bilberry
461 (Vaccinium myrtillus L.). 2. Boca Raton: CRC Press/Taylor & Francis, Boca Raton (FL)		(<i>Vaccinium myrtillus L.</i>). 2. Boca Raton: CRC Press/Taylor & Francis, Boca Raton (FL)
462 2011.		2011.
463 7 He J, Monica Giusti M. Anthocyanins: Natural colorants with health-promoting	7	7 He J, Monica Giusti M. Anthocyanins: Natural colorants with health-promoting
464 properties. Annu Rev Food Sci Technol. 2010;1:163–87. doi:	Ļ	
465 10.1146/annurev.food.080708.100754		

466	8	Kent K, Charlton K, Roodenrys S, <i>et al.</i> Consumption of anthocyanin-rich cherry juice
467		for 12 weeks improves memory and cognition in older adults with mild-to-moderate
468		dementia. <i>Eur J Nutr</i> . 2017;56:333–41. doi: 10.1007/s00394-015-1083-y
469	9	Li S, Wang T, Fu W, <i>et al</i> . Role of Gut Microbiota in the Anti-Colitic Effects of
470		Anthocyanin-Containing Potatoes. <i>Mol Nutr Food Res</i> . 2021;65:1–14. doi:
471		10.1002/mnfr.202100152
472	10	Mo J, Ni J, Zhang M, <i>et al</i> . Mulberry Anthocyanins Ameliorate DSS-Induced Ulcerative
473		Colitis by Improving Intestinal Barrier Function and Modulating Gut Microbiota.
474		Antioxidants. 2022;11. doi: 10.3390/antiox11091674
475	11	Tian L, Tan Y, Chen G, et al. Metabolism of anthocyanins and consequent effects on the
476		gut microbiota. <i>Crit Rev Food Sci Nutr</i> . 2019;59:982–91. doi:
477		10.1080/10408398.2018.1533517
478	12	Farombi EO, Adedara IA, Awoyemi O V., <i>et al</i> . Dietary protocatechuic acid ameliorates
479		dextran sulphate sodium-induced ulcerative colitis and hepatotoxicity in rats. Food
480		Funct. 2016;7:913–21. doi: 10.1039/c5fo01228g
481	13	Li J, Wu T, Li N, et al. Bilberry anthocyanin extract promotes intestinal barrier function
482		and inhibits digestive enzyme activity by regulating the gut microbiota in aging rats.
483		Food Funct. 2019;10:333–43. doi: 10.1039/c8fo01962b
484	14	Biedermann L, Mwinyi J, Scharl M, <i>et al.</i> Bilberry ingestion improves disease activity in
485		mild to moderate ulcerative colitis - An open pilot study. J Crohns Colitis. 2013;7:271-
486		9. doi: 10.1016/j.crohns.2012.07.010
487	15	Biedermann L, Doulberis M, Schreiner P, <i>et al.</i> A Multi-Center Randomized, Double-
488		Blind, Placebo Controlled, Parallel Group, Phase IIa Study to Evaluate the Efficacy,
489		Safety and Tolerability of an Anthocyanin Rich Extract (ACRE) in Patients with
490		Ulcerative Colitis. <i>medRxiv</i> . 2024;2024.07.19.24310589. doi:
491		10.1101/2024.07.19.24310589
492	16	Review C, Communication S, Principles G. World Medical Association Declaration of
493	10	Helsinki: ethical principles for medical research involving human subjects. J Am Coll
494		<i>Dent</i> . 2014;81:14–8. doi: 10.1093/acprof:oso/9780199241323.003.0025
495	17	European Medicines Agency (EMA). Guideline Good Clinical Practice E6(R2).
496	11	Committee for Human Medicinal Products. 2018;6:1–68.
497	18	Tan C, Wang M, Kong Y, <i>et al.</i> Anti-inflammatory and intestinal microbiota modulation
498	10	properties of high hydrostatic pressure treated cyanidin-3-glucoside and blueberry
499		pectin complexes on dextran sodium sulfate-induced ulcerative colitis mice. <i>Food</i>
500		<i>Funct</i> . 2022;4384–98. doi: 10.1039/d1fo03376j
500	19	Moon HJ, Cha YS, Kim KA. Blackcurrant Alleviates Dextran Sulfate Sodium (DSS)-
501	19	Induced Colitis in Mice. <i>Foods</i> . 2023;12. doi: 10.3390/foods12051073
502	20	Wu B, Cox AD, Chang H, <i>et al.</i> Maize near-isogenic lines with enhanced flavonoids
503	20	alleviated dextran sodium sulfate-induced murine colitis via modulation of the gut
		•
505 506	21	microbiota. <i>Food Funct</i> . 2023;14:9606–16. doi: 10.1039/d3fo02953k
506	21	Gevers D, Kugathasan S, Denson LA, <i>et al.</i> The Treatment-Naive Microbiome in New-
507		Onset Crohn's Disease. <i>Cell Host Microbe</i> . 2014;15:382–92. doi:
508	22	10.1016/j.chom.2014.02.005
509	22	Lloyd-Price J, Arze C, Ananthakrishnan AN, <i>et al.</i> Multi-omics of the gut microbial
510		ecosystem in inflammatory bowel diseases. <i>Nature</i> . 2019;569:655–62. doi:
511		10.1038/s41586-019-1237-9

512	23	Kansal S, Catto-Smith AG, Boniface K, <i>et al.</i> The Microbiome in Paediatric Crohn's
513		Disease—A Longitudinal, Prospective, Single-Centre Study. J Crohns Colitis.
514		2019;13:1044–54. doi: 10.1093/ecco-jcc/jjz016
515	24	Putignani L, Oliva S, Isoldi S, <i>et al.</i> Fecal and mucosal microbiota profiling in pediatric
516		inflammatory bowel diseases. <i>Eur J Gastroenterol Hepatol</i> . 2021;33:1376–86. doi:
517		10.1097/MEG.0000000000002050
518	25	Schirmer M, Denson L, Vlamakis H, <i>et al.</i> Compositional and Temporal Changes in the
519		Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course.
520		<i>Cell Host Microbe</i> . 2018;24:600-610.e4. doi: 10.1016/j.chom.2018.09.009
521	26	Barberio B, Facchin S, Patuzzi I, et al. A specific microbiota signature is associated to
522		various degrees of ulcerative colitis as assessed by a machine learning approach. Gut
523	~-	Microbes. 2022;14:1–12. doi: 10.1080/19490976.2022.2028366
524	27	Čipčić Paljetak H, Barešić A, Panek M, <i>et al</i> . Gut microbiota in mucosa and feces of
525		newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable
526		bowel syndrome patients. <i>Gut Microbes</i> . 2022;14:1–21. doi:
527 528	20	10.1080/19490976.2022.2083419
528 529	28	Shapiro JM, de Zoete MR, Palm NW, <i>et al.</i> Immunoglobulin A Targets a Unique Subset of the Microbiota in Inflammatory Bowel Disease. <i>Cell Host Microbe</i> . 2021;29:83-
529		93.e3. doi: 10.1016/j.chom.2020.12.003
531	29	Pabst O. New concepts in the generation and functions of IgA. <i>Nat Rev Immunol</i> .
532	25	2012;12:821–32. doi: 10.1038/nri3322
533	30	Chow J, Tang H, Mazmanian SK. Pathobionts of the gastrointestinal microbiota and
534		inflammatory disease. Curr Opin Immunol. 2011;23:473–80. doi:
535		10.1016/j.coi.2011.07.010
536	31	Palm NW, De Zoete MR, Cullen TW, <i>et al.</i> Immunoglobulin A coating identifies
537		colitogenic bacteria in inflammatory bowel disease. <i>Cell</i> . 2014;158:1000–10. doi:
538		10.1016/j.cell.2014.08.006
539	32	Shapiro JM, Cho JH, Sands BE, et al. Bridging the gap between host immune response
540		and intestinal dysbiosis in inflammatory bowel disease: Does immunoglobulin a mark
541		the spot? <i>Clinical Gastroenterology and Hepatology</i> . 2015;13:842–6. doi:
542		10.1016/j.cgh.2015.02.028
543	33	Lin R, Chen H, Shu W, <i>et al</i> . Clinical significance of soluble immunoglobulins A and G
544		and their coated bacteria in feces of patients with inflammatory bowel disease. J
545		Transl Med. 2018;16:1–15. doi: 10.1186/s12967-018-1723-0
546	34	Gupta S, Basu S, Bal V, et al. Gut IgA abundance in adult life is a major determinant of
547		resistance to dextran sodium sulfate-colitis and can compensate for the effects of
548		inadequate maternal IgA received by neonates. <i>Immunology</i> . 2019;158:19–34. doi:
549	25	10.1111/imm.13091
550	35	Liu X, Wang L, Zhuang H, <i>et al.</i> Promoting intestinal IgA production in mice by oral
551		administration with anthocyanins. <i>Front Immunol</i> . 2022;13. doi:
552	26	10.3389/fimmu.2022.826597
553 554	36	Taira T, Yamaguchi S, Takahashi A, <i>et al.</i> Dietary polyphenols increase fecal mucin and immunoglobulin A and ameliorate the disturbance in gut microbiota caused by a high
554 555		fat diet. <i>J Clin Biochem Nutr</i> . 2015;57:212–6. doi: 10.3164/jcbn.15-15
556		ac alea. 5 chil Diochem Matt. 2015,57.212 0. doi: 10.5104/jcbii.15-15
557		
557		

558 Supplementary Tables

Inclusion Criteria	Exclusion Criteria			
Male or female ≥18 years of age	Acute fulminant UC and/or signs of systemic toxicity			
Established diagnosis of UC, with minimum time from diagnosis of ≥3 months	UC limited to the rectum (disease which extends <15cm above the anal verge)			
Moderately at least left sided UC (disease should extend 15cm or more above the anal verge). Disease severity determined by a Modified Mayo Score of 6 to 12 with an endoscopic sub score ≥ 2 assessed by central reading of endoscopy performed at screening visit and no other individual sub score <1 Current oral or rectal 5-ASA/SP use or a history of oral or rectal 5-ASA/SP use	Suspicion of differential diagnosis such as: Crohn's, enterocolitis, ischaemic colitis, radiation colitis, indeterminate colitis, infectious colitis, diverticular disease, associated colitis, microscopic colitis, massive pseudopolyposis or non- passable stenosis Serious active infection or current history of active infection			
	Gastrointestinal infections including positive Clostridium difficile stool assay			
Current steroids use or history of steroids dependency, refractory, or intolerance, including no steroids treatment due to earlier side-effects (only one of the steroids criteria have to be fulfilled, see definition in European Crohn's and Colitis organization (ECCO) guidelines)	History or presence of any clinically significant disorder that, in option of the investigator, could impact on patient's possibility to adhere to the protocol and protocol procedures or would confound the study result or compromise patient safety			
One of the following points must be fulfilled:	History of malignancy, except for:			
 Active disease despite in duction therapy with 5-ASA agents where ade quate therapy is considered with an oral 5-ASA (mesalamine 2-4.8g/day, sulfasalazine 4-6g/day) administered for at least 2 weeks. Topical treatment with 5-ASA may have been attempted but this is not a prere quisite for inclusion in the study Intolerance to oral 5-ASAs or azathioprine Active disease despite a thiopurine (adequately dosed according to treatment guidelines, such as 2-3 mg/kg for azathioprine) or methotrexate administered for at least 12 weeks Active disease despite treatment with biologicals or calcineurin inhibitors 	Treated (cured) basal cell or squamous cell in situ carcinoma Treated (cured) cervical intraepithelial neoplasia Carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years prior to the screening visit Presence or history of underlying metabolic, endocrine, hematologic, pulmonary, cardiac, blood, renal, hepatic, infectious, psychiatric or any medically unstable condition as assessed by the primary treating physician which, in the option of the investigator, would place the subject at unacceptable risk for participation in the study Significant illness within the two weeks prior to dosing or any active infection a medical condition that may require treatment or therapeutic intervention during the study			
	Known history of alcohol abuse, chronic liver or biliary disease			
	History or presence of a significant renal disease			
 Allowed to receive a therapeutic dose of following UC drugs during the study: Oral steroids therapy (≤30mg prednisone or equivalent/day) providing that the dose has been stable for 2 weeks prior to baseline Oral or rectal MMX Budesonide therapy (9mg/day) initiated at least 8 weeks before baseline Oral or rectal 5-ASA/SP compounds, providing that the dose has been stable for 2 weeks before baseline Allowed to reckel 5-ASA/SP compounds, providing that the dose has been stable for 2 weeks before baseline visit AZA/6-MP providing that the dose has been stable for 8 weeks prior to baseline and been initiated at least 2 months before screening 	Long term treatment with antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs) within two weeks prior to screening (one short treatment regime for antibiotics and occasional use of NSAIDs are allowed) Antibiotics within the last week prior to randomization, subjects who received cyclosporine or tacrolimus within the last 4 weeks prior to randomization and c dose of >30mg/day or equivalent per kg body weight in the last 4 weeks prior to randomization			
 TNF inhibitors (Infliximab, Adalimumab or Golimumab) are allowed, providing that the dose is stable for at least 2 months prior to baseline and during the study treatment period Vedolizumab and Tofacitinib is allowed, providing that the dose is stable for at least 2 months prior to baseline and during the study 	Subjects who have been treated with a dose of ≥1mg per kg body weight prednisone or ≥30mg/day in the last 4 weeks prior to randomization Ongoing treatment with cyclosporine or tacrolimus. Eligible subjects must have stopped cyclosporine and tacrolimus at least 4 weeks and antibiotics at least 1			
treatment period	week prior to randomization.			
	Currently receiving parenteral nutrition or blood transfusions			
	Planned diet change, any severe or new dietary restrictions			
	Known allergies to bilberries or any other AC containing fruits			
Ability to understand the treatment, willingness to comply all study requirements and ability to provide informed consent	Concurrent participation in another clinical study with investigational therapy or previous use of investigational therapy within 5 half-lives and within at leas 30 days after last treatment of the experimental product prior to enrolment Females who are lactating or have a positive serum pregnancy test during the screening period			
39	Repeated and confirmed laboratory findings showing total bilirubin >2xULN unless in Gilbert's syndrome AP >2xULN ALT>2xULN serum creatinine >2xULN white blood cell count outside the range of 3,000-15,000 per μL platelet count < 100,000 per μl			



Supplementary Table 1 : Detailled inclusion and exclusion criteria

561

Study Periods	Screening	Treatmen	t Period			Follow- up
Visit	5	В	1	2	3	FUP
Day	-28 to -0	1 = Baseline	15± 4d	28± 4d	56± 4d	86± 4d
Subject Information and Informed Consent	x					
Demographics	x					
Medical History	x					
Update Medical History		x	X	x	x	x
In- /Exclusion Criteria	x	x				
Physical Examination	x	x	X	x	x	x
Vital Signs (pulse, blood pressure, temperature), Body Weight, Body	x	x	x	x	x	x
Height ¹ Serum Laboratory Tests (Safety Lab) 2	x	x	x	x	x	x
Pregnancy Test ³	x	x	x	x	x	x
Urine analysis	x	x	x	x	x	x
Fecal Samples, stool bacteriology, C. diff.	x					
Fecal Calprotectin	X	x	X	X	X	X
Microbiota Analyses	x	x	X	x	x	x
Resting-ECG	x					
Sigmoidoscopy with 6 Biopsies and Endoscopic Mayo Subcore and Histology (Geboes Index) Recording for central reading	x				x	
Complete Mayo Score	X				x	
Partial Mayo Score (including PRO2)	x	x	x	x	x	X
Dispense Subject Diaries ⁴	x	x	x	x	x	
Collect Subject Diaries ⁴		x	x	x	x	x
Assess quality of life (SIBDQ ⁴ , EuroQoL5D)	x	x	x	x	x	x
Distribution and/ or collecting of Study Medication		x	x	x	x	x (if applicab
Concomitant Therapy	x	x	x	x	x	X
Adverse Events and Serious Adverse Events		x	x	x	x	x
 ¹ only at screening ² including hematology, blood chemistry ³Screening with serum pregnancy test, other visits with urine stick test ⁴ SIBDQ = Short Inflammatory Bowel Disease Questionnaire, Patient Diary (including stool frequency, abdominal pain and general well-being) indicated 						
in appendix						

573

Supplementary Table 2: Detailed study procedure description

574

576 Supplementary Table 3. Indivdiually significant associations between genus abundance and

577 faecal calprotectin concentrations prior to the intervention.


578

Genus	No.samples	Slope	Lower bound	Upper bound	р	FDR
Haemophilus	53	0.259	0.114	0.405	0.000832	0.00419
Parasutterella	46	-0.221	-0.345	-0.0963	0.000931	0.00419
TF01-11	44	0.192	0.0588	0.326	0.00578	0.0173
Hungatella_A	42	0.234	0.0532	0.416	0.0122	0.024
Lachnospira	64	0.294	0.0633	0.524	0.0134	0.024
Lawsonibacter	65	-0.317	-0.602	-0.0328	0.0296	0.0435
Phascolarctobacterium	34	-0.135	-0.259	-0.011	0.0338	0.0435
An114	54	-0.231	-0.45	-0.0118	0.0393	0.0442
Anaerobutyricum	62	-0.239	-0.476	-0.00159	0.0486	0.0486

579


580





Supplementary Figure 1. Change in the concentration of faecal calprotectin throughout the study. a. Each small point shows the concentration of faecal calprotectin (μ g/g) in placebotreated (grey) or ACRE-treated (blue) subjects at the different time points. The large circles and squares show the group geometric means. The dashed and solid lines the mean slope for

placebo and ACRE, respectively, estimated from a linear mixed model with random slopes and intercepts for the two groups. **b.** Estimated intercept for each subject from the linear mixed model. **c.** Estimated slope for each subject from the linear mixed model (p = 0.036).



592

⁵⁹³ Supplementary Figure 2. The positive correlation of *Haemophilus* and faecal calprotectin 594 persists during the intervention in placebo-treated individuals. Each point corresponds to a 595 sample from a subject at a specific timepoint, visit 1 (circles), visit 2 (triangles), visit 3 596 (squares), follow-up (FU, +). The line shows the estimated regression slope from a linear 597 mixed model with subject as a random effect.